# US 2013/0158015 A1 · Dual mechanism inhibitors for the treatment of disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158015 A1
- Document ID: US20130158015A1
- Status: Published application
- Kind: A1
- Application number: 13/768,594
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2009-05-01
- Assignees: Aerie Pharmaceuticals, Inc.
- Inventors: Mitchell A. deLong; Jill Marie Sturdivant; Susan M. Royalty
- Web page: https://patentgrep.com/patent/US20130158015A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/18: Feminine contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 237/20: the carbon skeleton containing six-membered aromatic rings
- C07C 237/42: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C07D 217/00: Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 217/24: Oxygen atoms
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/40: Thiophene-2-carboxylic acid
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

## Claims

### Claim 1

A compound according to Formula II:
and salts thereof,
wherein R1, R2, and R3 are independently hydrogen, C1-C4 alkyl, aryl, C1-C4 alkyl aryl, C1-C4 alkyl heteroaryl, C1-C4 alkyl heterocyclyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, C1-C4 carboxyl, or form a ring with each other or with A;
wherein A is C1-C4 alkyl, or forms a ring structure with R1, R2, or R3;
wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C1-C22 alkyl, C1-C22 alkyl aryl, C1-C22 alkyl heteroaryl, C2-C22 alkenyl, C2-C22 alkynyl, C1-C22 carbonyl, C1-C22 carbonylamino, C1-C22 alkoxy, C1-C22 sulfonyl, C1-C22 sulfonylamino, C1-C22 thioalkyl, or C1-C22 carboxyl;
wherein X1, X2, and X3 are, independently, hydrogen, hydroxyl, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, amino, aminocarbonyl, nitro, cyano, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, or C1-C4 carboxyl;
wherein the double circle indicates an aromatic or heteroaromatic ring; and
wherein each Z is independently a bond, C1-C4 alkyl, heteroalkyl, or an O atom.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is hydrogen or C1-C4 alkyl; B is C1-C22 carbonyl; X1, X2, and X3 are hydrogen; the double circle indicates an aromatic or heteroaromatic ring; and Z is a bond, C1-C4 alkyl, C1-C4 heteroalkyl, or an O atom.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein Z is a bond or —CH2—.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein X1, X2 and X3 are each hydrogen.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein A is —CH2CH2—.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R1 and R2 are independently hydrogen or methyl.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R3 is hydrogen or C1-C4 alkyl.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

A method for treating a disease in a subject comprising:
administering to a subject an effective amount of a compound according to claim 1; wherein the disease comprises eye disease.

### Claim 10 (depends on 9)

The method of claim 9, wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.

### Claim 11 (depends on 1)

A method of modulating kinase activity comprising:
contacting a cell with a compound according to claim 1 in an amount effective to modulate kinase activity.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell is in a subject.

### Claim 13 (depends on 1)

A method of reducing intraocular pressure comprising:
contacting a cell with a compound according to claim 1 in an amount effective to reduce intraocular pressure.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cell is in a subject.
